Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA HALCION REVIEW IS EXAMINING AT LEAST TWO NEW ALLEGATIONS

Executive Summary

FDA HALCION REVIEW IS EXAMINING AT LEAST TWO NEW ALLEGATIONS raised in an investigative report that resulted from a December 1991-March 1992 inspection of Upjohn's facilities. The agency said it will evaluate the entire report but focus on what information appears to be new, such as allegations from the FDA investigators' establishment inspection report (EIR) that Upjohn misrepresented data to gain approval for use of Halcion beyond 14 days and that Upjohn hid from FDA the death of a patient taking Xanax (alprazolam) during clinical development.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024401

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel